British Medical Journal Apologizes To Lilly For Prozac Article
This article was originally published in The Pink Sheet Daily
Executive Summary
In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”
You may also be interested in...
Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims
Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.
Rep. Hinchey Calls On FDA To Investigate Agency Knowledge Of Prozac Data
Rep. Maurice Hinchey (D-N.Y.) requests that FDA conduct an investigation into what the agency did or did not know about Lilly documents regarding a possible link between Prozac (fluoxetine) and increased suicidality and violence
“Missing” Lilly Documents Under Review By Rep. Hinchey
The documents allegedly suggest that Lilly was aware of a link between Prozac and suicidality as early as the 1980s. Hinchey is expected to issue a statement regarding the documents by Jan. 7.